Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
- PMID: 9573066
- PMCID: PMC108140
- DOI: 10.1128/IAI.66.5.1891-1897.1998
Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
Abstract
Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases.
Figures
![FIG. 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab5/108140/0a4645ca9a72/ii0581520001.gif)
![FIG. 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab5/108140/36d2c7a15d3b/ii0581520002.gif)
![FIG. 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab5/108140/a97ccb53b76e/ii0581520003.gif)
Similar articles
-
Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.Infect Immun. 2005 May;73(5):2790-6. doi: 10.1128/IAI.73.5.2790-2796.2005. Infect Immun. 2005. PMID: 15845482 Free PMC article.
-
Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.Infect Immun. 1996 Oct;64(10):4047-53. doi: 10.1128/iai.64.10.4047-4053.1996. Infect Immun. 1996. PMID: 8926067 Free PMC article.
-
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.Vaccine. 2011 Jun 6;29(25):4210-7. doi: 10.1016/j.vaccine.2011.03.102. Epub 2011 Apr 16. Vaccine. 2011. PMID: 21501641 Free PMC article.
-
Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections.Microbes Infect. 2000 Apr;2(5):561-8. doi: 10.1016/s1286-4579(00)00310-5. Microbes Infect. 2000. PMID: 10865201 Review.
-
Vaccines for Moraxella catarrhalis.Vaccine. 2000 Dec 8;19 Suppl 1:S101-7. doi: 10.1016/s0264-410x(00)00287-5. Vaccine. 2000. PMID: 11163472 Review.
Cited by
-
Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.Infect Immun. 2005 May;73(5):2790-6. doi: 10.1128/IAI.73.5.2790-2796.2005. Infect Immun. 2005. PMID: 15845482 Free PMC article.
-
The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro.J Bacteriol. 2000 Mar;182(5):1364-73. doi: 10.1128/JB.182.5.1364-1373.2000. J Bacteriol. 2000. PMID: 10671460 Free PMC article.
-
Moraxella catarrhalis: from emerging to established pathogen.Clin Microbiol Rev. 2002 Jan;15(1):125-44. doi: 10.1128/CMR.15.1.125-144.2002. Clin Microbiol Rev. 2002. PMID: 11781271 Free PMC article. Review.
-
Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.Infect Immun. 2008 Sep;76(9):4251-8. doi: 10.1128/IAI.01570-07. Epub 2008 Jun 16. Infect Immun. 2008. PMID: 18559429 Free PMC article.
-
Roles of 3-deoxy-D-manno-2-octulosonic acid transferase from Moraxella catarrhalis in lipooligosaccharide biosynthesis and virulence.Infect Immun. 2005 Jul;73(7):4222-30. doi: 10.1128/IAI.73.7.4222-4230.2005. Infect Immun. 2005. PMID: 15972513 Free PMC article.
References
-
- Ahmed K, Rikitomi N, Ichinose A, Matsumoto K. Possible presence of a capsule in Branhamella catarrhalis. Microbiol Immunol. 1991;35:361–366. - PubMed
-
- Alaeus, A., and G. Stiernstedt.Branhamella catarrhalis septicemia in an immunocompetent adult. Scand. J. Infect. Dis. 23:115–116. - PubMed
-
- Bluestone, C. D. 1986. Otitis media and sinusitis in children. Role of Branhamella catarrhalis. Drugs 31(Suppl. 3):132–141. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources